Beta Bionics Faces Class Action Over iLet Insulin Pump Allegations

SAN DIEGO, Sept. 7, 2026 /CourierPR/ -- Beta Bionics Inc, a commercial-stage medical device company known for its automated insulin delivery system, iLet, is facing a class action lawsuit over alleged misrepresentations regarding the safety and efficacy of its product. The lawsuit, filed by the shareholder rights law firm Robbins LLP, alleges that during a specific period, the company’s statements to investors were misleading.

The class action, which pertains to investors who purchased or otherwise acquired Beta Bionics Inc (NASDAQ: BBNX) common stock between July 30, 2025, and February 24, 2026, seeks to represent those who suffered losses during the period. The core of the complaint centers on the company’s claims about the safety, efficacy, and commercial success of its iLet insulin pump. According to the lawsuit, these claims were based on a misinterpretation of FDA reporting requirements, which later turned out to be false.

In October 2025, the company disclosed receipt of an FDA Form 483, which raised concerns about the iLet device. Beta Bionics maintained that the letter did not pertain to the safety or efficacy of the device and instead stated that the issue revolved around a minor compliance matter. However, the lawsuit alleges that the FDA had identified significant issues, including the device malfunctioning and dosing patients with dangerously high levels of insulin, leading to hypoglycemic events.

Further disclosures on January 8, 2026, and culminating on February 24, 2026, revealed that the issues were far more extensive than initially reported. On February 24, 2026, the full extent of the problem was exposed when the FDA publicly released its warning letter, detailing a series of violations and the company’s failure to address them. This revelation caused a significant drop in Beta Bionics’ stock price, from $31.99 per share on January 9, 2026, to $12.89 per share by February 25, 2026.

Investors who purchased the company’s stock during the class period may be eligible to participate in the lawsuit. Robbins LLP is urging investors who suffered significant losses to contact the firm before the November 3, 2026, lead plaintiff deadline. The law firm is offering a contingency fee basis, meaning no upfront costs are required for participation.

According to Brian J. Robbins, a founding partner of Robbins LLP, “Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently.” The lawsuit seeks to hold Beta Bionics accountable for its alleged misrepresentations and to restore value to shareholders affected by the company’s missteps.